 Gilead Sciences, Inc. Nasdaq: GILD and Galapagos NV Euronext Nasdaq: GLPG announced today the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion for Jyseleca filgotinib 200 mg and 100 mg tablets, an investigational, once-daily, oral, selective JAK1 inhibitor for the treatment of adults with moderate to severe rheumatoid arthritis RA who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs DMARDs. The CHMP positive opinion is a scientific recommendation to the European Commission to grant marketing authorization in Europe. 